Medulloblastoma: signalling a change in treatment.
Medulloblastoma is the most common malignant brain tumour that occurs during childhood. Multimodality treatment regimens have substantially improved survival in this disease; however, the tumour is incurable in about a third of patients with medulloblastoma, and current treatment has a detrimental effect on long-term survivors. Drugs that target cell-signalling pathways provide an alternative to conventional cytotoxic approaches to treatment of cancer. Several pathways have been implicated in medulloblastoma formation, and knowledge of these is now being used to develop new ways of treating children with medulloblastoma.
Gilbertson
Richard J
RJ
Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Richard.Gilbertson@stjude.org
D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000502:physiology; D053823:Hedgehog Proteins; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000187:drug effects* / Q000494:pharmacology*; D012307:Risk Factors; D015398:Signal Transduction; D015534:Trans-Activators / Q000096:biosynthesis / Q000494:pharmacology; D051153:Wnt Proteins; D029961:Zebrafish Proteins
D053823:Hedgehog Proteins; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D051153:Wnt Proteins; D029961:Zebrafish Proteins; D066246:ErbB Receptors